Minireviews
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Ophthalmol. Aug 12, 2015; 5(3): 125-132
Published online Aug 12, 2015. doi: 10.5318/wjo.v5.i3.125
Intravitreal drug administration for treatment of noninfectious uveitis
Alper Yazici, Pinar C Ozdal
Alper Yazici, Department of Ophthalmology, Balıkesir University School of Medicine, 10145 Balıkesir, Turkey
Pinar C Ozdal, Department of Ophthalmology, Ulucanlar Eye Training and Research Hospital, 06240 Ankara, Turkey
Author contributions: Both authors contributed to this manuscript.
Conflict-of-interest statement: None of the authors have conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Alper Yazici, MD, Assistant Professor, Department of Ophthalmology, Balıkesir University School of Medicine, 17. Km Bigadic Road, Cagis Campus Balikesir University Hospital, 10145 Balikesir, Turkey. lpryzc@yahoo.com
Telephone: +90-50-53937586 Fax: +90-21-66121023
Received: February 25, 2015
Peer-review started: February 26, 2015
First decision: April 10, 2015
Revised: May 26, 2015
Accepted: June 15, 2015
Article in press: June 16, 2015
Published online: August 12, 2015
Core Tip

Core tip: The limitations related to the systemic use of treatment options in noninfectious posterior uveitis yielded intravitreal route. The hallmark of intravitreal treatment triamcinolone acetonide has a short half-life with a high rate of intraocular complications, and this led to the development of implants as a treatment option with various agents in the market still under investigation. In this review, we try to summarize the intravitreal therapeutic options that are being used in noninfectious uveitis.